Vera Therapeutics, Inc.
VERA
$39.96
-$1.21-2.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -96.92% | -87.49% | -102.39% | -86.06% | -58.50% |
| Total Depreciation and Amortization | 345.71% | 618.52% | 686.11% | -66.73% | 400.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 138.38% | 137.36% | 124.50% | 90.91% | 53.01% |
| Change in Net Operating Assets | 764.36% | 806.47% | 196.08% | 111.89% | 145.69% |
| Cash from Operations | -79.02% | -74.31% | -73.59% | -55.69% | -46.10% |
| Capital Expenditure | 35.19% | -200.77% | -740.79% | -1,739.68% | -1,442.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 145.96% | 42.29% | 33.38% | 30.13% | -977.16% |
| Cash from Investing | 145.71% | 41.78% | 32.81% | 29.72% | -977.91% |
| Total Debt Issued | -- | -5.67% | -5.67% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.47% | 17.21% | 17.38% | 19.58% | 456.55% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.39% | -39.18% | -39.18% | -19.50% | -440.61% |
| Cash from Financing | -49.08% | 14.08% | 14.23% | 9.79% | 354.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 458.03% | 16,595.68% | 373.01% | 79.56% | 2,334.68% |